Close Menu

NEW YORK – Qiagen and Inovio Pharmaceuticals said on Wednesday that they have signed a new master collaboration agreement to develop liquid biopsy companion diagnostic tests based on next-generation sequencing to complement Inovio's therapies.

The initial project of the expanded collaboration focuses on the development of a diagnostic test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with human papillomavirus infection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.